Company: EDSA
Filing Date: 2025-09-09
Form Type: 424B5
Source: 0001171843-25-005799
Chunk: 0

Company: Edesa Biotech, Inc.
Filing Date: 2025-09-09
Form: 424B5
Chunk 0
---
Filed Pursuant to Rule 424(b)(5)

Registration No. 333-288966

### PROSPECTUS SUPPLEMENT
(To Prospectus dated September 9, 2025)

<div align='center'>Up to $4,006,544

Common Shares</div>

**We have entered into an At The Market Offering Agreement dated October
4, 2024 (the “Sales Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright” or the “Sales Agent”),
relating to our common shares, no par value (“common shares”), offered by this prospectus supplement and the accompanying
prospectus. In accordance with the terms of the Sales Agreement, from time to time we may offer and sell our common shares through Wainwright
acting as sales agent or principal. Pursuant to this prospectus supplement and the accompanying prospectus, from time to time we may offer
and sell our common shares having an aggregate offering price of up to $4,006,544. As of September 9, 2025, we have issued and sold an
aggregate of 304,057 of our common shares for gross proceeds of $837,134 pursuant to the Sales Agreement and the related prospectus supplement,
dated October 4, 2024 to the Company’s Registration Statement on Form S-3 (333-266604).

Our common shares are traded on the Nasdaq Capital Market of the Nasdaq
Stock Market LLC (“Nasdaq”) under the symbol “EDSA.” On September 5, 2025, the last reported sale price of our
common shares on Nasdaq was $2.53 per share.

Sales of our common shares, if any, under this prospectus
supplement and the accompanying prospectus may be made in sales deemed to be an “at the market offering” as defined in Rule
415(a)(4) promulgated under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on
or through the Nasdaq Capital Market, the existing trading market for our common shares, or any other existing trading market in the United
States for our common shares, sales made to or through a market maker other than on an exchange or otherwise, directly to Wainwright as
principal, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices,
and/or in any other method permitted by law. Subject to terms of the